Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis
Posted on Fri, Jan 14, 2011
Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study
Therapeutic Advances in Neurological Disorders, 01/14/2011 Exclusive author commentary
Uitdehaag B et al. – The findings of these post hoc analyses suggest that high exposure to sc interferon beta–1a may be associated with better clinical outcomes than low exposure, and also highlight the importance of maximizing adherence. Additional prospective investigation is warranted to evaluate further the effects of treatment exposure on outcomes and to determine the benefits of interventions to improve adherence.
Victor Rivera. (01/13/2011) comments:
This multi authored international ad hoc analyses addresses long-term follow-up, 7-8 years, after enrolment in the PRISMS (Prevention of Relapses and disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) study. Patients exposed to 44 mcg high dose and that received continuous therapy had better clinical outcomes (annual relapse rate, progression of disability and conversion to secondary progressive disease) as well as...read more
Read all Neurology articles at MDLinx.com